Tags Archive Navigation
icon
-
Media ReleaseNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients
-
Media ReleaseNew data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis
-
Media ReleaseNovartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
-
Media ReleaseSandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
-
StoryExpanding a new digital healthcare solution across chronic heart disease management
-
Media ReleaseAveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1
-
Media ReleaseAveXis Announces Proposed Public Offering of Common Stock
-
Media ReleaseAveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
-
Media ReleaseREGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
-
Media ReleaseAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
-
Media ReleaseAveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pagination
- ‹ Previous page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- …
- 31
- › Next page